학술논문
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Document Type
Journal Article
Author
Berger, Anne Katrin; Lücke, Stephan; Abel, Ulrich; Haag, Georg Martin; Grüllich, Carsten; Stange, Annika; Dietrich, Mareike; Apostolidis, Leonidas; Freitag, Angelika; Trierweiler, Claudia; von Gall, Carl; Ose, Jennifer; Giesel, Frederik; Weber, Tim Frederik; Lordick, Florian; Haberkorn, Uwe; Jäger, Dirk
Source
Subject
Language
ISSN
0007-0920
Abstract